This phenomenon held true in other AML model cell lines, both promyelocytic (NB4) and non-promyelocytic (OCI-AML2, THP-1, Fig. 5d-e), where different combinations were tested based on their responsiveness to the individual agents (Additional file 2: Figure S3B). This evidence concerns the gene RUNX3 and acute myeloid leukemia.